Rapid improvement of depression and psychotic symptoms in Huntington's disease: a retrospective chart review of seven patients treated with electroconvulsive therapy.

Cusin C, Franco FB, Fernandez-Robles C, DuBois CM, Welch CA.

Gen Hosp Psychiatry. 2013 Nov-Dec;35(6):678.e3-5. doi: 10.1016/j.genhosppsych.2013.01.015.

Cognition in Huntington's disease in manifest, premanifest and converting gene carriers over ten years.

Hart EP, Dumas EM, Giltay EJ, Middelkoop HA, Roos RA.

J Huntingtons Dis. 2013;2(2):137-47. doi: 10.3233/JHD-130059.

Noninvasive brain stimulation in Huntington's disease.

Berardelli A, Suppa A.

Handb Clin Neurol. 2013;116:555-60. doi: 10.1016/B978-0-444-53497-2.00044-9. Review.

Acute rheumatic fever with chorea.

Buonuomo PS, Macchiaiolo M, Toscano A, De Benedetti F, Villani A, Bartuli A.

Arch Dis Child. 2013 Mar;98(3):203. doi: 10.1136/archdischild-2012-302732. No abstract available.

Defective mitochondrial disulfide relay system, altered mitochondrial morphology and function in Huntington's disease.

Napoli E, Wong S, Hung C, Ross-Inta C, Bomdica P, Giulivi C.

Hum Mol Genet. 2013 Mar 1;22(5):989-1004. doi: 10.1093/hmg/dds503.

CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease.

Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR.

J Med Genet. 2013 Oct;50(10):696-703. doi: 10.1136/jmedgenet-2013-101796.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304.

Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease.

Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M.

PLoS One. 2013 Dec 19;8(12):e84726. doi: 10.1371/journal.pone.0084726.

BDNF prevents NMDA-induced toxicity in models of Huntington's disease: the effects are genotype specific and adenosine A2A receptor is involved.

Martire A, Pepponi R, Domenici MR, Ferrante A, Chiodi V, Popoli P.

J Neurochem. 2013 Apr;125(2):225-35. doi: 10.1111/jnc.12177.

A randomized feasibility study of a 12-week community-based exercise program for people with Huntington's disease.

Busse M, Quinn L, Debono K, Jones K, Collett J, Playle R, Kelly M, Simpson S, Backx K, Wasley D, Dawes H, Rosser A; Members of the COMMET-HD Management Group..

J Neurol Phys Ther. 2013 Dec;37(4):149-58. doi: 10.1097/NPT.0000000000000016.

Physical therapy in Huntington's disease--toward objective assessments?

Bohlen S, Ekwall C, Hellström K, Vesterlin H, Björnefur M, Wiklund L, Reilmann R.

Eur J Neurol. 2013 Feb;20(2):389-93. doi: 10.1111/j.1468-1331.2012.03760.x.

Epigenetic mechanisms of neurodegeneration in Huntington's disease.

Lee J, Hwang YJ, Kim KY, Kowall NW, Ryu H.

Neurotherapeutics. 2013 Oct;10(4):664-76. doi: 10.1007/s13311-013-0206-5. Review.

Huntington disease: How many repeats does it take?

Hogarth P.

Neurology. 2013 May 28;80(22):e241-3. doi: 10.1212/WNL.0b013e3182984b31. No abstract available.

Analysis of gait and balance through a single triaxial accelerometer in presymptomatic and symptomatic Huntington's disease.

Dalton A, Khalil H, Busse M, Rosser A, van Deursen R, Ólaighin G.

Gait Posture. 2013 Jan;37(1):49-54. doi: 10.1016/j.gaitpost.2012.05.028.

Selective executive dysfunction but intact risky decision-making in early Huntington's disease.

Holl AK, Wilkinson L, Tabrizi SJ, Painold A, Jahanshahi M.

Mov Disord. 2013 Jul;28(8):1104-9. doi: 10.1002/mds.25388.